The new San Diego facility will function as a critical node in Novartis’s integrated global research network, connecting seamlessly with existing research hubs in Basel, Switzerland, and Cambridge, Massachusetts.
This partnership with Novartis creates a vital platform to increase awareness of chronic urticaria among dermatologists and other healthcare professionals.
This new 35,000 square foot, purpose-built site represents Novartis’s fourth dedicated RLT facility.